Trial reportCancer gene therapy2006
Liposome-DNA complexes infused intravenously inhibit tumor angiogenesis and elicit antitumor activity in dogs with soft tissue sarcoma.
Trial report in Cancer gene therapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 63 citations in OpenAlex.
- Contributions of large and agricultural animal models to immunology.Journal of immunology (Baltimore, Md. : 1950) · 2025Review
- Novel ocular immunotherapy induces tumor regression in an equine model of ocular surface squamous neoplasia.Cancer immunology, immunotherapy : CII · 2023Article
- Application of Biocompatible Drug Delivery Nanosystems for the Treatment of Naturally Occurring Cancer in Dogs.Journal of functional biomaterials · 2022Review
- Article
- Preliminary evaluation of fecal fatty acid concentrations in cats with chronic kidney disease and correlation with indoxyl sulfate and p-cresol sulfate.Journal of veterinary internal medicine · 2020Article
- Article
- Local immune and microbiological responses to mucosal administration of a Liposome-TLR agonist immunotherapeutic in dogs.BMC veterinary research · 2019Article
- The Use of Liposomes and Nanoparticles as Drug Delivery Systems to Improve Cancer Treatment in Dogs and Cats.Molecules (Basel, Switzerland) · 2017Review
- Manipulation of Innate Immunity for Cancer Therapy in Dogs.Veterinary sciences · 2015Review
- Clinical trials of immunogene therapy for spontaneous tumors in companion animals.TheScientificWorldJournal · 2014Review
- Liposomal clodronate treatment for tumour macrophage depletion in dogs with soft-tissue sarcoma.Veterinary and comparative oncology · 2013Article
- Recent developments in liposome-based veterinary therapeutics.ISRN veterinary science · 2013Review
- Depletion of phagocytic myeloid cells triggers spontaneous T cell- and NK cell-dependent antitumor activity.Oncoimmunology · 2012Article
- Potential of amino acid/dipeptide monoester prodrugs of floxuridine in facilitating enhanced delivery of active drug to interior sites of tumors: a two-tier monolayer in vitro study.Pharmaceutical research · 2011Article
- A non-coding cationic lipid DNA complex produces lasting anti-leukemic effects.Cancer biology & therapy · 2010Article
- Type I interferons inhibit the generation of tumor-associated macrophages.Cancer immunology, immunotherapy : CII · 2010Article
- Liposome-nucleic acid immunotherapeutics.Expert opinion on drug delivery · 2008Review
- Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma.Cancer immunology, immunotherapy : CII · 2007Article
- Vaccination with liposome--DNA complexes elicits enhanced antitumor immunity.Cancer gene therapy · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
Intravenous gene delivery using liposome-DNA complexes (LDC) has previously been shown to elicit antitumor activity, but only in rodent tumor models. Therefore, we conducted a study to determine in a large animal spontaneous tumor model whether intravenous infusions of LDC could target gene expression to cutaneous tumor tissues and whether repeated treatments had an effect on tumor growth or angiogenesis. A total of 13 dogs with cutaneous soft tissue sarcomas were enrolled in the study and were randomized to receive a series of 6 weekly infusions of LDC containing either canine endostatin DNA or DNA encoding an irrelevant gene (luciferase). Serial tumor biopsies were obtained to assess transgene expression, tumor microvessel density (MVD), and intratumoral leukocyte inflammatory responses. We found that intravenous infusion of LDC did not result in detectable gene expression in cutaneous tumor tissues. However, two of 13 treated dogs had objective tumor responses and eight dogs had stable disease during the treatment period. In addition, a significant decrease in tumor MVD was noted in six of 12 treated dogs at the completion of six treatments. These results suggest that intravenous infusions of LDC may elicit nonspecific antitumor activity and inhibit tumor angiogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.